Paraoxonase Status in Coronary Heart Disease
Top Cited Papers
- 1 September 2001
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 21 (9) , 1451-1457
- https://doi.org/10.1161/hq0901.094247
Abstract
Human serum paraoxonase (PON1) hydrolyzes oxidized lipids in low density lipoprotein (LDL) and could therefore retard the development of atherosclerosis. In keeping with this hypothesis, several case-control studies have shown a relationship between the presence of coronary heart disease (CHD) and polymorphisms at amino acid positions 55 and 192 of PON1, which we associated with a decreased capacity of PON1 to protect LDL against the accumulation of lipid peroxides, but some other studies have not. However, the PON1 polymorphisms are only 1 factor in determining the activity and concentration of the enzyme. Only 3 of the previous 18 studies directly determined PON1 activity and concentration. Therefore, we studied PON1 activity, concentration, and gene distribution in 417 subjects with angiographically proven CHD and in 282 control subjects. We found that PON1 activity and concentration were significantly lower in subjects with CHD than in control subjects (activity to paraoxon 122.8 [3.3 to 802.8] versus...Keywords
This publication has 52 references indexed in Scilit:
- Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in RabbitsBiochemical and Biophysical Research Communications, 2000
- Paraoxonase activity in two healthy populations with differing rates of coronary heart diseaseEuropean Journal of Clinical Investigation, 2000
- Mutations in the human paraoxonase 1 genePharmacogenetics, 1999
- Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipientsKidney International, 1999
- Lack of Protection against Oxidative Modification of LDL by Avian HDLBiochemical and Biophysical Research Communications, 1998
- Paraoxonase gene polymorphism in Japanese subjects with coronary heart diseaseInternational Journal of Cardiology, 1996
- Oxidative status of lipoproteins in coronary disease patientsAmerican Heart Journal, 1992
- High-density lipoprotein inhibits the oxidative modification of low-density lipoproteinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- Beyond CholesterolNew England Journal of Medicine, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986